CAR T‑cell therapy for gastric cancer: Potential and perspective (Review)
- Authors:
- Bo Long
- Long Qin
- Boya Zhang
- Qiong Li
- Long Wang
- Xiangyan Jiang
- Huili Ye
- Genyuan Zhang
- Zeyuan Yu
- Zuoyi Jiao
-
Affiliations: Department of First General Surgery, Lanzhou University Second Hospital, Lanzhou, Gansu 730000, P.R. China, The Cuiying Center, Lanzhou University Second Hospital, Lanzhou, Gansu 730000, P.R. China, Department of Endocrinology, The First Hospital of Lanzhou University, Lanzhou, Gansu 730000, P.R. China - Published online on: February 12, 2020 https://doi.org/10.3892/ijo.2020.4982
- Pages: 889-899
This article is mentioned in:
Abstract
 |
 |
 |
|
Khalil DN, Budhu S, Gasmi B, Zappasodi R, Hirschhorn-Cymerman D, Plitt T, De Henau O, Zamarin D, Holmgaard RB, Murphy JT, et al: The new era of cancer immunotherapy: Manipulating T-cell activity to overcome malignancy. Adv Cancer Res. 128:1–68. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, et al: Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 17:4550–4557. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Schuster M, Nechansky A and Kircheis R: Cancer immunotherapy. Biotechnol J. 1:138–147. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Fesnak AD, June CH and Levine BL: Engineered T cells: The promise and challenges of cancer immunotherapy. Nat Rev Cancer. 16:566–581. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Chow VA, Shadman M and Gopal AK: Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma. Blood. 132:777–781. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Grupp SA, Michael K, David B, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF, et al: Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 368:1509–1518. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, Yang JC, Phan GQ, Hughes MS, Sherry RM, et al: Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 33:540–549. 2015. View Article : Google Scholar : | |
|
Wang Z, Wu Z, Liu Y and Han W: New development in CAR-T cell therapy. J Hematol Oncol. 10:532017. View Article : Google Scholar : PubMed/NCBI | |
|
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, Bonaventure A, Valkov M, Johnson CJ, Estève J, et al: Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): Analysis of individual records for 37513025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 391:1023–1075. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
FDA approves second CAR T-cell therapy. Cancer Discov. 8:5–6. 2018. View Article : Google Scholar | |
|
June CH, O'Connor RS, Kawalekar OU, Ghassemi S and Milone MC: CAR T cell immunotherapy for human cancer. Science. 359:1361–1365. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Han Y, Liu C, Li G, Li J, Lv X, Shi H, Liu J, Liu S, Yan P, Wang S, et al: Antitumor effects and persistence of a novel HER2 CAR T cells directed to gastric cancer in preclinical models. Am J Cancer Res. 8:106–119. 2018.PubMed/NCBI | |
|
Han H, Wang S, Hu Y, Li Z, Yang W, Lv Y, Wang L, Zhang L and Ji J: Monoclonal antibody 3H11 chimeric antigen receptors enhance T cell effector function and exhibit efficacy against gastric cancer. Oncol Lett. 15:6887–6894. 2018.PubMed/NCBI | |
|
Kim M, Pyo S, Kang CH, Lee CO, Lee HK, Choi SU and Park CH: Folate receptor 1 (FOLR1) targeted chimeric antigen receptor (CAR) T cells for the treatment of gastric cancer. PLoS One. 13:e01983472018. View Article : Google Scholar : PubMed/NCBI | |
|
Song Y, Tong C, Wang Y, Gao Y, Dai H, Guo Y, Zhao X, Wang Y, Wang Z, Han W and Chen L: Effective and persistent antitumor activity of HER2-directed CAR-T cells against gastric cancer cells in vitro and xenotransplanted tumors in vivo. Protein Cell. 9:867–878. 2018. View Article : Google Scholar : | |
|
Luo F, Qian J, Yang J, Deng Y, Zheng X, Liu J and Chu Y: Bifunctional αHER2/CD3 RNA-engineered CART-like human T cells specifically eliminate HER2(+) gastric cancer. Cell Res. 26:850–853. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Gross G, Waks T and Eshhar Z: Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA. 86:10024–10028. 1989. View Article : Google Scholar : PubMed/NCBI | |
|
Eshhar Z, Waks T, Gross G and Schindler DG: Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA. 90:720–724. 1993. View Article : Google Scholar : PubMed/NCBI | |
|
Jaspers JE and Brentjens RJ: Development of CAR T cells designed to improve antitumor efficacy and safety. Pharmacol Ther. 178:83–91. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Brocker T and Karjalainen K: Signals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes. J Exp Med. 181:1653–1659. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Finney HM, Lawson AD, Bebbington CR and Weir AN: Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J Immunol. 161:2791–2797. 1998.PubMed/NCBI | |
|
Savoldo B, Ramos CA, Liu E, Mims MP, Keating MJ, Carrum G, Kamble RT, Bollard CM, Gee AP, Mei Z, et al: CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest. 121:1822–1826. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Brentjens RJ, Rivière I, Park JH, Davila ML, Wang X, Stefanski J, Taylor C, Yeh R, Bartido S, Borquez-Ojeda O, et al: Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 118:4817–4828. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, Bartido S, Stefanski J, Taylor C, Olszewska M, et al: CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 5:177ra382013. View Article : Google Scholar : PubMed/NCBI | |
|
Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A and June CH: T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 3:95ra732011. View Article : Google Scholar : PubMed/NCBI | |
|
Finney HM, Akbar AN and Lawson AD: Activation of resting human primary T cells with chimeric receptors: Costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain. J Immunol. 172:104–113. 2004. View Article : Google Scholar | |
|
Knochelmann HM, Smith AS, Dwyer CJ, Wyatt MM, Mehrotra S and Paulos CM: CAR T cells in solid tumors: Blueprints for building effective therapies. Front Immunol. 9:17402018. View Article : Google Scholar : PubMed/NCBI | |
|
Ramos CA and Gianpietro D: Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy. Expert Opin Biol Ther. 11:855–873. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Jackson HJ, Rafiq S and Brentjens RJ: Driving CAR T-cells forward. Nat Rev Clin Oncol. 13:370–383. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Till BG, Jensen MC, Wang J, Qian X, Gopal AK, Maloney DG, Lindgren CG, Lin Y, Pagel JM, Budde LE, et al: CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: Pilot clinical trial results. Blood. 119:3940–3950. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Porter DL, Levine BL, Kalos M, Bagg A and June CH: Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 365:725–733. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Jensen MC and Riddell SR: Designing chimeric antigen receptors to effectively and safely target tumors. Curr Opin Immunol. 33:9–15. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
McAdam AJ, Greenwald RJ, Levin MA, Chernova T, Malenkovich N, Ling V, Freeman GJ and Sharpe AH: ICOS is critical for CD40-mediated antibody class switching. Nature. 409:102–105. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Lipowska-Bhalla G, Gilham DE, Hawkins RE and Rothwell DG: Targeted immunotherapy of cancer with CAR T cells: Achievements and challenges. Cancer Immunol Immunother. 61:953–962. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Haynes NM, Trapani JA, Teng MW, Jackson JT, Cerruti L, Jane SM, Kershaw MH, Smyth MJ and Darcy PK: Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. Blood. 100:3155–3163. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Wu J, Song Y, Bakker AB, Bauer S, Spies T, Lanier LL and Phillips JH: An activating immunoreceptor complex formed by NKG2D and DAP10. Science. 285:730–732. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Pulè MA, Straathof KC, Dotti G, Heslop HE, Rooney CM and Brenner MK: A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther. 12:933–941. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Milone MC, Fish JD and Carmine C: Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther. 17:1453–1464. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Hua Z, Snyder KM, Suhoski MM, Maus MV, Kapoor V, June CH and Mackall CL: 4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy. J Immunol. 179:4910–4918. 2007. View Article : Google Scholar | |
|
Friedmann-Morvinski D, Bendavid A, Waks T, Schindler D and Eshhar Z: Redirected primary T cells harboring a chimeric receptor require costimulation for their antigen-specific activation. Blood. 105:30872005. View Article : Google Scholar : PubMed/NCBI | |
|
Porter DL, Hwang WT, Frey NV, Lacey SF, Shaw PA, Loren AW, Bagg A, Marcucci KT, Shen A, Gonzalez V, et al: Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 7:303ra1392015. View Article : Google Scholar : PubMed/NCBI | |
|
Kawalekar OU, O'Connor RS, Fraietta JA, Guo L, McGettigan SE, Posey AD Jr, Patel PR, Guedan S, Scholler J, Keith B, et al: Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity. 44:380–390. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Maude SL, Noelle F, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, et al: Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 371:1507–1517. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Cheadle EJ, Rothwell DG, Bridgeman JS, Sheard VE, Hawkins RE and Gilham DE: Ligation of the CD2 co-stimulatory receptor enhances IL-2 production from first-generation chimeric antigen receptor T cells. Gene Ther. 19:1114–1120. 2012. View Article : Google Scholar | |
|
Han S, Latchoumanin O, Wu G, Zhou G, Hebbard L, George J and Qiao L: Recent clinical trials utilizing chimeric antigen receptor T cells therapies against solid tumors. Cancer Lett. 390:188–200. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA, Maric I, Raffeld M, Nathan DA, Lanier BJ, et al: Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood. 116:4099–4102. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Y, Zhang WY, Han QW, Liu Y, Dai HR, Guo YL, Bo J, Fan H, Zhang Y, Zhang YJ, et al: Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells. Clin Immunol. 155:160–175. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Till BG, Jensen MC, Wang J, Chen EY, Wood BL, Greisman HA, Qian X, James SE, Raubitschek A, Forman SJ, et al: Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood. 112:2261–2271. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang WY, Wang Y, Guo YL, Dai HR, Yang QM, Zhang YJ, Zhang Y, Chen MX, Wang CM, Feng KC, et al: Treatment of CD20-directed Chimeric Antigen Receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: An early phase IIa trial report. Signal Transduct Target Ther. 1:160022016. View Article : Google Scholar : PubMed/NCBI | |
|
Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, Stetler-Stevenson M, Phan GQ, Hughes MS, Sherry RM, et al: B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 119:2709–2720. 2012. View Article : Google Scholar : | |
|
Locke FL, Neelapu SS, Bartlett NL, Siddiqi T, Chavez JC, Hosing CM, Ghobadi A, Budde LE, Bot A, Rossi JM, et al: Phase 1 results of ZUMA-1: A multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma. Mol Ther. 25:285–295. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Kochenderfer JN, Somerville RPT, Lu T, Shi V, Bot A, Rossi J, Xue A, Goff SL, Yang JC, Sherry RM, et al: Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels. J Clin Oncol. 35:1803–1813. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, et al: Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 377:2531–2544. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak Ö, Brogdon JL, Pruteanu-Malinici I, Bhoj V, Landsburg D, et al: Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med. 377:2545–2554. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA, White DE, Wunderlich JR, Canevari S, Rogers-Freezer L, et al: A phase I study on adoptive immuno-therapy using gene-modified T cells for ovarian cancer. Clin Cancer Res. 12:6106–6115. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Lamers CH, Sleijfer S, Vulto AG, Kruit WH, Kliffen M, Debets R, Gratama JW, Stoter G and Oosterwijk E: Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: First clinical experience. J Clin Oncol. 24:e20–e22. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Guo Y, Wang Y and Han W: Chimeric antigen receptor-modified T cells for solid tumors: Challenges and prospects. J Immunol Res. 2016:38508392016. View Article : Google Scholar : PubMed/NCBI | |
|
Sadelain M, Brentjens R and Rivière I: The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol. 21:215–223. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Fousek K and Ahmed N: The evolution of T-cell therapies for solid malignancies. Clin Cancer Res. 21:3384–3392. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Lamers CH, Langeveld SC, Grootvan Ruijven CM, Debets R, Sleijfer S and Gratama JW: Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo. Cancer Immunol Immunother. 56:1875–1883. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G, Huls MH, Liu E, Gee AP, Mei Z, et al: Virus-specific T cells engineered to coexpress tumor-specific receptors: Persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 14:1264–1270. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Brown CE, Badie B, Barish ME, Weng L, Ostberg JR, Chang WC, Naranjo A, Starr R, Wagner J, Wright C, et al: Bioactivity and safety of IL13Rα2-redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma. Clin Cancer Res. 21:4062–4072. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Whilding LM and Maher J: ErbB-targeted CAR T-cell immunotherapy of cancer. Immunotherapy. 7:229–241. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Fanotto V, Ongaro E, Rihawi K, Avallone A, Silvestris N, Fornaro L, Vasile E, Antonuzzo L, Leone F, Rosati G, et al: HER-2 inhibition in gastric and colorectal cancers: Tangible achievements, novel acquisitions and future perspectives. Oncotarget. 7:69060–69074. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Jiang J, Zhang Y, Chuai S, Wang Z, Zheng D, Xu F, Zhang Y, Li C, Liang Y and Chen Z: Trastuzumab (herceptin) targets gastric cancer stem cells characterized by CD90 phenotype. Oncogene. 31:671–682. 2012. View Article : Google Scholar | |
|
Lo PK and Chen H: Cancer stem cells and cells of origin in MMTV-Her2/neu-induced mammary tumorigenesis. Oncogene. 32:1338–1340. 2013. View Article : Google Scholar | |
|
Shah D, Wyatt D, Baker AT, Simms P, Peiffer DS, Fernandez M, Rakha E, Green A, Filipovic A, Miele L and Osipo C: Inhibition of HER2 increases JAGGED1-dependent breast cancer stem cells: Role for membrane JAGGED1. Clin Cancer Res. 24:4566–4578. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Plaks V, Kong N and Werb Z: The cancer stem cell niche: How essential is the niche in regulating stemness of tumor cells? Cell Stem Cell. 16:225–238. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Nagorsen D, Kufer P, Baeuerle PA and Bargou R: Blinatumomab: A historical perspective. Pharmacol Ther. 136:334–342. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Sun M, Shi H, Liu C, Liu J, Liu X and Sun Y: Construction and evaluation of a novel humanized HER2-specific chimeric receptor. Breast Cancer Res. 16:1–10. 2014. View Article : Google Scholar | |
|
Schönfeld K, Sahm C, Zhang C, Naundorf S, Brendel C, Odendahl M, Nowakowska P, Bönig H, Köhl U, Kloess S, et al: Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor. Mol Ther. 23:330–338. 2015. View Article : Google Scholar : | |
|
Rainusso N, Brawley VS, Ghazi A, Hicks MJ, Gottschalk S, Rosen JM and Ahmed N: Immunotherapy targeting HER2 with genetically modified T cells eliminates tumor-initiating cells in osteosarcoma. Adv Exp Med Biol. 19:212–217. 2012. | |
|
Hartmann J, Schüßler-Lenz M, Bondanza A and Buchholz CJ: Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts. EMBO Mol Med. 9:1183–1198. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET and Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI | |
|
Schag CC, Heinrich RL and Ganz PA: Karnofsky performance status revisited: Reliability, validity, and guidelines. J Clin Oncol. 2:187–193. 1984. View Article : Google Scholar : PubMed/NCBI | |
|
Frey NV and Porter DL: Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2016:567–572. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Ali SA, Shi V, Maric I, Wang M, Stroncek DF, Rose JJ, Brudno JN, Stetler-Stevenson M, Feldman SA, Hansen BG, et al: T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood. 128:1688–1700. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM and Rosenberg SA: Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 18:843–851. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Kim MG, Kim D, Suh SK, Park Z, Choi MJ and Oh YK: Current status and regulatory perspective of chimeric antigen receptor-modified T cell therapeutics. Arch Pharm Res. 39:437–452. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Teachey DT, Lacey SF, Shaw PA, Melenhorst JJ, Maude SL, Frey N, Pequignot E, Gonzalez VE, Chen F, Finklestein J, et al: Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov. 6:664–679. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Brudno JN and Kochenderfer JN: Toxicities of chimeric antigen receptor T cells: Recognition and management. Blood. 127:3321–3330. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Brudno JN and Kochenderfer JN: Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management. Blood Rev. 34:45–55. 2019. View Article : Google Scholar : | |
|
Park JH, Rivière I, Gonen M, Wang X, Sénéchal B, Curran KJ, Sauter C, Wang Y, Santomasso B, Mead E, et al: Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 378:449–459. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Thistlethwaite FC, Gilham DE, Guest RD, Rothwell DG, Pillai M, Burt DJ, Byatte AJ, Kirillova N, Valle JW, Sharma SK, et al: The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity. Cancer Immunol Immunothe. 66:1425–1436. 2017. View Article : Google Scholar | |
|
Gross G and Eshhar Z: Therapeutic potential of T cell chimeric antigen receptors (CARs) in cancer treatment: Counteracting off-tumor toxicities for safe CAR T cell therapy. Annu Rev Pharmacol Toxicol. 56:59–83. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Kenderian SS, Ruella M, Shestova O, Klichinsky M, Aikawa V, Morrissette JJ, Scholler J, Song D, Porter DL, Carroll M, et al: CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia. Leukemia. 29:1637–1647. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Lamers CH, Sleijfer S, van Steenbergen S, van Elzakker P, van Krimpen B, Groot C, Vulto A, den Bakker M, Oosterwijk E, Debets R and Gratama JW: Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: Clinical evaluation and management of on-target toxicity. Mol Ther. 21:904–912. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Mei H, Jiang H, Wu Y, Guo T, Xia L, Jin R and Hu Y: Neurological toxicities and coagulation disorders in the cytokine release syndrome during CAR-T therapy. Br J Haematol. 181:689–692. 2018. View Article : Google Scholar | |
|
Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, Chung SS, Stefanski J, Borquez-Ojeda O, Olszewska M, et al: Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 6:224ra252014. View Article : Google Scholar : PubMed/NCBI | |
|
Schultz DR and Arnold PI: Properties of four acute phase proteins: C-reactive protein, serum amyloid A protein, alpha 1-acid glycoprotein, and fibrinogen. Semin Arthritis Rheum. 20:129–147. 1990. View Article : Google Scholar : PubMed/NCBI | |
|
Lee DW, Kochenderfer JN, Stetlerstevenson M, Cui YK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Sabatino M, Shah NN, et al: T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose-escalation trial. Lancet. 385:517–528. 2015. View Article : Google Scholar | |
|
Lee DW, Rebecca G, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA and Mackall CL: Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 124:188–195. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Pardridge WM: CNS drug design based on principles of blood-brain barrier transport. J Neurochem. 70:1781–1792. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Brudno JN, Maric I, Hartman SD, Rose JJ, Wang M, Lam N, Stetler-Stevenson M, Salem D, Yuan C, Pavletic S, et al: T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma. J Clin Oncol. 36:2267–2280. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD, et al: Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 378:439–448. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Beatty GL and O'Hara M: Chimeric antigen receptor-modified T cells for the treatment of solid tumors: Defining the challenges and next steps. Pharmacol Ther. 166:30–39. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Sharma P and Allison JP: The future of immune checkpoint therapy. Science. 348:56–61. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Kang TH, Mao CP, Lee SY, Chen A, Lee JH, Kim TW, Alvarez RD, Roden RB, Pardoll D, Hung CF and Wu TC: Chemotherapy acts as an adjuvant to convert the tumor microenvironment into a highly permissive state for vaccination-induced antitumor immunity. Cancer Res. 73:2493–2504. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Shahabi V, Postow MA, Tuck D and Wolchok JD: Immune-priming of the tumor microenvironment by radiotherapy: Rationale for combination with immunotherapy to improve anticancer efficacy. Am J Clin Oncol. 38:90–97. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Nanki K, Toshimitsu K, Takano A, Fujii M, Shimokawa M, Ohta Y, Matano M, Seino T, Nishikori S, Ishikawa K, et al: Divergent routes toward Wnt and R-spondin niche independency during human gastric carcinogenesis. Cell. 174:856–869.e17. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Hidalgo M, Amant F, Biankin AV, Budinská E, Byrne AT, Caldas C, Clarke RB, de Jong S, Jonkers J, Mælandsmo GM, et al: Patient-derived xenograft models: An emerging platform for translational cancer research. Cancer Discov. 4:998–1013. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Lv J, Zhao R, Wu D, Zheng D, Wu Z, Shi J, Wei X, Wu Q, Long Y, Lin S, et al: Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer. J Hematol Oncol. 12:182019. View Article : Google Scholar : PubMed/NCBI |
